Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UMS4

UPID:
PRP19_HUMAN

ALTERNATIVE NAMES:
Nuclear matrix protein 200; PRP19/PSO4 homolog; RING-type E3 ubiquitin transferase PRP19; Senescence evasion factor

ALTERNATIVE UPACC:
Q9UMS4

BACKGROUND:
The Pre-mRNA-processing factor 19, known by aliases such as Nuclear matrix protein 200 and RING-type E3 ubiquitin transferase PRP19, is integral to several cellular mechanisms, including mRNA splicing and DNA repair pathways. It mediates 'Lys-63'-linked polyubiquitination essential for spliceosome assembly and function, and is involved in the DNA damage response by ubiquitinating RPA1 and RPA2, facilitating the recruitment of repair complexes. PRP19's ubiquitin ligase activity also plays a role in proteasomal degradation, highlighting its multifunctionality in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Pre-mRNA-processing factor 19 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.